BrainStorm Granted “Outperform” Rating by Murphy Analytics
New York and Petach Tikvah, Israel Oct. 27, 2009 – BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced today that Murphy Analytics, an equity research group, has Initiated Coverage on Brainstorm and granted Brainstorm with an Outperform Rating.
To view Murphy Analytic's report click the link below:
http://www.murphyanalytics.com/uploads/BCLI_Initiation
Rami Efrati, CEO of BrainStorm Cell Therapeutics, states, "We are very pleased with the quality of Murphy Analytics research coverage. The report provides serious investors with an in-depth understanding of our Company and what we believe to be a tremendous opportunity for creating outstanding returns for our shareholders. Murphy Analytics sees upside in both the near and long term and has initiated coverage on BCLI with an Outperform rating."
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.
Murphy Analytics was compensated $3,720 for this report on Brainstorm Cell Therapeutics by Emerging Markets Consulting, LLC.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including BrainStorm's ability to complete its equity financing transactions previously disclosed. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; minimal working capital and difficulty raising additional capital, dependence on its license to Ramot's technology; ability, together with its licensor, to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.
BrainStorm Cell Therapeutics
Rami Efrati, CEO, +972-3-9236384
efrati@brainstorm-cell.com
Press Releases
